Clinical Trials Logo

Rotavirus Gastroenteritis clinical trials

View clinical trials related to Rotavirus Gastroenteritis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05958771 Recruiting - Clinical trials for Rotavirus Gastroenteritis

The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E

Start date: July 6, 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, phase 3 study to evaluate the Efficacy, Safety, and Immunogenicity of ROTAVAC 5D, a live attenuated rotavirus vaccine in healthy infants. A total of 5800 healthy Chilean infants will be recruited in this study and randomized to receive either vaccine or placebo in 1:1 ratio. Among these participants 300 will be categorized to immunogenicity cohort, 150 from each group, and blood samples will be collected to assess the immune response.

NCT ID: NCT01061658 Recruiting - Clinical trials for Rotavirus Gastroenteritis

Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine

Start date: July 2010
Phase: Phase 1/Phase 2
Study type: Interventional

A double blind placebo controlled Phase I/II study to evaluate the safety and immunogenicity of the Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]in Indian infants. The study would be carried out in 90 healthy infants. Three doses of the rotavirus vaccine or placebo would be administered orally to each infant at 6-8, 10-12 and 14-16 weeks of age. The rotavirus vaccine would be administered at one of the two planned virus concentrations (10e5.5 or 10e6.25 FFU of each constituent serotype per 0.5 ml). Each administration of the vaccine/placebo would be preceded by oral administration of 2.0 mL of antacid.